Meeting Banner
Abstract #3746

MRI based assessment of cerebrovascular pathology in Alzheimer’s disease

Ying Xia1, Nawaf Yassi2,3, Pierrick Bourgeat1, Parnesh Raniga1, Patricia Desmond4, Jurgen Fripp1, David Ames5,6, Paul Maruff3,7, Chris Fowler3, Ralph Martins8, Victor Villemagne9,10, Collin Masters3, Christopher Rowe9,10, and Olivier Salvado1

1The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, Australia, 2Departments of Medicine and Neurology, The Royal Melbourne Hospital, Parkville, Australia, 3Florey Institute of Neuroscience and Mental Health Research, Parkville, Australia, 4Department of Radiology, The Royal Melbourne Hospital, University of Melbourne, Parkville, Australia, 5National Ageing Research Institute, Melbourne, Australia, 6Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Australia, 7Cogstate, Melbourne, Australia, 8Centre of Excellence for Alzheimer’s Disease Research and Care, Edith Cowan University, Joondalup, Australia, 9Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia, 10Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia

Cerebrovascular disease often coexists with Alzheimer’s disease (AD) and its contribution to the development of AD remains unclear. This study assessed cerebrovascular pathology in terms of brain infarction and white matter hyperintensities (WMH) in the AIBL study, and investigated its impact on amyloid deposition. Our data revealed significantly greater WMH burden and higher prevalence of cerebrovascular pathology in AD patients. No correlation was found between amyloid load and WMH in either healthy controls, mild cognitive impairment or AD. Moreover, the presence of cerebrovascular pathology showed no association with amyloid deposition in subjects with or without AD.

This abstract and the presentation materials are available to members only; a login is required.

Join Here